Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Mylan

The Best Covered Call Strategy to Trade High-Yielding Pfizer Stock and Earn Extra Income

Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start. Pfizer (PFE) has been a strong performer in 2026 and is up 9.64% so far this year.

Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case

The Novo Nordisk A/S (NYSE:NVO) attempt to block Mylan Pharmaceuticals from launching a generic version of its weight-loss drug Wegovy hit a major obstacle as the court ruled in Mylan's favor on key infringement claims related to U.S. Patent No. 9,764,003.

2 Covered Call Ideas on Pfizer Stock

2 Covered Call Ideas on Pfizer Stock

Today, we’re looking at two covered call examples on Pfizer stock. The first step to finding our covered call candidates is to use the Stock Scanner with the following parameters:

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

How to Buy PFE For a 6% Discount, or Achieve a 23% Annual Return

Selling cash secured puts on stocks an investor is happy to take ownership of is a great way to generate some extra income.

2 Covered Call Ideas on Pfizer Stock

Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start.

Telangana DCA cancels Mylan Laboratories alprazolam manufacturing licence

Telangana Drugs Control Administration cancels Mylan Laboratories' manufacturing license for alprazolam due to unauthorized diversion of the drug.

How to Buy PFE For a 7% Discount, or Achieve a 16% Annual Return

Selling cash secured puts on stocks an investor is happy to take ownership of is a great way to generate some extra income.

inkl

Read news from The Economist, FT, and more,
with one subscription

Is the Rally Getting Long in the Tooth? Try These Bear Call Spread Trades

Is the Rally Getting Long in the Tooth? Try These Bear Call Spread Trades

Traders should have a bearish outlook on the stock and ideally look to enter when the stock has a high implied volatility rank.

Manchin war chest could help, and hurt, if he runs in 2024

Should Sen. Joe Manchin III seek reelection next year, the West Virginia Democrat would almost certainly rely on a network of K Street lobbyists, corporate executives and out-of-state donors to help fund his campaign.

Tribune News Service

Manchin war chest could help, and hurt, if he runs in 2024 - Roll Call

Manchin war chest could help, and hurt, if he runs in 2024 - Roll Call

Sen. Joe Manchin has a $9 million campaign account but could face heat for raising less than 2 percent in his home state of West Virginia.

Short Circuit: A Roundup of Recent Federal Court Decisions

Measles, tough weeds, and a COVID hoax.

Median pay for executives at the largest companies surged last year. A few shareholders are crying foul

While it's surely not worth dwelling over, it nonetheless merits note: The highest-paid CEOs and their top-level colleagues rake in more money in one year — typically way more — than most of us will see in a lifetime.

Tribune News Service

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Viatris To Pay $264M As EpiPen Antitrust Litigation Settlement: Reuters

Viatris To Pay $264M As EpiPen Antitrust Litigation Settlement: Reuters

Viatris Inc (NASDAQ: VTRS), previously known as Mylan, has

Get all your
news in one place.

100's of premium titles.
One news app.

India-Based Biocon To Buy Viatris' Biosimilars Assets In $3.3B Deal

Biocon Biologics Ltd has agreed to acquire Viatris Inc's (NASDAQ:VTRS) biosimilars assets for up to $3.335 billion in stock and cash. The deal value includes cash of up to $2.335 billion and Compulsorily Convertible Preference Shares in Biocon Biologics, valued at $1 billion. Viatris will also pay $50 million to Biocon Biologics to fund…

Viatris Recalls One Batch Of Diabetes Treatment Semglee Citing Missing Label Risks

Viatris Inc's (NASDAQ: VTRS) Mylan will pull one batch of non-interchangeable Semglee, also known as insulin glargine injection.

1

People

Joe Manchin III

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Republican Party

Eleventh Circuit

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play